Jeffrey Richard Thill, M.D North Mills Avenue Orlando, FL 32803

Size: px

Start display at page:

Download "Jeffrey Richard Thill, M.D North Mills Avenue Orlando, FL 32803"

Merry George
6 years ago
Views:

1 Jeffrey Richard Thill, M.D North Mills Avenue Orlando, FL CURRENT POSITION AFFILIATIONS BIRTHPLACE BOARD CERTIFIED UROLOGIST WINTER PARK UROLOGY ASSOCIATES, P.A NORTH MILLS AVENUE, ORLANDO, FL Present STAFF UROLOGIST, WINTER PARK MEMORIAL HOSPITAL STAFF UROLOGIST, FLORIDA HOSPITAL, ORLANDO CLINICAL PROFESSOR OF UROLOGY, SHANDS HOSPITAL UNIVERSITY OF FLORIDA CLINICAL ASSISTANT PROFESSOR FLORIDA STATE UNIVERSITY SCHOOL OF MEDICINE MEMBER, ORANGE COUNTY MEDICAL SOCIETY MEMBER, FLORIDA MEDICAL ASSOCIATION MEMBER, AMERICAN UROLOGICAL ASSOCIATION KANSAS CITY, MISSOURI AUGUST 1, 1962 FAMILY STATUS MARRIED TO KARIN BUTTON THILL, R.N., 1983 ONE CHILD, LEVI, BORN APRIL 2, 1985 EDUCATION B.A., MCPHERSON COLLEGE UNIVERSITY OF IOWA M.D., UNIVERSITY OF IOWA POST-GRADUATE GENERAL SURGERY UNIVERSITY OF FLORIDA JULY 1988-JUNE 1990 DEPARTMENT OF UROLOGY UNIVERSITY OF FLORIDA JULY LICENSURE FLORIDA #ME FLEX 1989 IN-TRAINING EXAMINATIONS UROLOGY TH PERCENTILE UROLOGY RD PERCENTILE UROLOGY TH PERCENTILE AWARDS SUMMA CUM LAUDE-MCPHERSON COLLEGE 1984 RECOGNITIONS UROLOGY FOUNDATION IN-SERVICE AWARD 1991, 1992 WISE OWL AWARD, FLORIDA UROLOGIC SOCIETY TARPON SPRINGS, FL, 1991 UNIVERSITY OF FLORIDA UROLOGY RESEARCH AWARD,

2 MEMBERSHIPS FLORIDA MEDICAL ASSOCIATION AMERICAN MEDICAL ASSOCIATION FLORIDA UROLOGICAL SOCIETY AMERICAN UROLOGICAL ASSOCIATION SOCIETY OF LAPAROENDOSCOPIC SURGEONS PUBLICATIONS "EFFECTS OF THE ANTIMITOCHONDRIAL AGENTS PRESENTATIONS LONIDAMINE AND DOXYCYCLINE AGAINST HUMAN RENAL CARCINOMA CELLS" PRESENTATION AT AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW ORLEANS, LA, MAY 1988 "WHAT'S THE CAUSE OF ABNORMALLY COLORED URINE" M. S. COHEN AND J. R. THILL, CONTEMPORARY UROLOGY, JUNE 1992 "ANTENATAL BLADDER RUPTURE: A COMPLICATION OF INTERVENTION FOR OBSTRUCTIVE UROPATHY" J. R. THILL AND R. D. WALKER, PRESENTATION AT SOUTHEASTERN SECTION, APRIL 1993, NASHVILLE, TN Research A Randomized, Double-Blind, Comparative Trial of a Study Drug Versus Placebo in Patients with Early Prostate Cancer A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Study Drug 0.5 Mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia A Phase III Efficacy and Safety Study Comparing Escalating Doses of Study Drug to 5 mg or 6 mg Doses of Study Drug or Placebo in the Treatment of Male Erectile Dysfunction A Study to Evaluate the Impact of Study Drug on Treatment Satisfaction A Phase III, Long-Term, Open-Label, Flexible Dose, and Safety Extension Study of Study Drug in the Treatment of Male Erectile Dysfunction A Phase III at Home Use Study Evaluating the Efficacy and Safety of Escalating Doses of Study Drug 2, 3, and 4 mg in the Treatment with Erectile Dysfunction A Study to Evaluate the Efficacy and Safety of a Study Drug Versus Placebo in Subjects with Overactive 2

3 Bladder A Phase III, Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of a Controlled Release Study Drug Versus A Study Drug in the Treatment of Subjects with Overactive Bladder A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study Comparing the Safety, Tolerance, and Efficacy of a Study Drug in Patients with Detrusor Hyperreflexia A Randomized, Double-Blind, Multi-Centre, Fixed Dose, Parallel-Group Twelve Month Study to Investigate the Safety and Tolerability of a Study Drug in the Treatment of Patients with Erectile Dysfunction A phase III, Randomized, Multicenter, Placebo Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of Study Drug for the Treatment of Hot Flashes Following Surgical of Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients A Phase IV, Open-label, Multi-Center, Large Community Based Study with an Eight Week Treatment Period to Evaluate the Satisfaction and Experience with Replacement Therapy A Phase IV, Open-Label, Multicenter, Community- Based Trial of Study Drug for the Treatment of Urogenital Symptoms in Postmenopausal Women A Patient Acceptability Study of a Once-Daily Formulation of Study Drug. A Phase IIIB, Open- Label, Single-Arm Trial in Adult Patients With Overactive Bladder and Symptoms of Urinary Frequency, Urgency, and/or Urge Incontinence A Multicenter Trial of Induction and 6 Courses of 3 Week Maintenance With BCG Versus BCG Plus Interferon Alfa-2B (Intron A) In Superficial Bladder Cancer A Multi-center, Multinational Open Clinical Study to Explore Relationships between Genotypic 3

4 (from DNA) and Serologic (from serum) Findings and Phenotypic Manifestations in a Large Cohort of Participants A Phase IIb/III Chemoprevention Trial of Study Drug to Prevent the Recurrence of Superficial Bladder Cancer Prospective, Randomized, Double-Blind Multi- Center, Fixed Dose, Parallel-Group Twelve Month Extension of Study XXXXX to Investigate the Safety and Tolerability of the Study Drug in the Treatment of Patients with Erectile Dysfunction over a Total Exposure Time of 24 Months A Phase III, Double-Blind, Randomized, Parallel Study Evaluating the Safety and Efficacy of Study Drug in the Treatment of Male Erectile Dysfunction Double-Blind, Placebo Controlled Study of Sustained Release Study Drug in Subjects with Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence An Investigation Of The NMP22 Point of Care POC) Device As An Aid In The Monitoring Of Bladder Cancer Patients An Investigation Of The NMP22 Point Of Care POC) Device As An Aid In The Screening Of Patients At Risk For Bladder Cancer A Phase 3B, Multi-Center, Double-Blind, Randomized, Placebo-Contolled, Parallel Group Study of Study Drug in Subjects with Overactive Bladder A Multicenter, Phase IIB, Four Arm, Dose Finding, Randomized, Placebo-Controlled Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20mg, 40mg & 60mg Daily of Study Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN) An Open-Label, Multicenter, Multinational Study to Determine the Safety and Efficacy of Study Drug Oral Solution in Children with Symptoms of Urge Urinary Incontinence Suggestive of Detrusor Instability An Open-label Trial on the Effect of IV Study Drug 4

5 4mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis A Randomized, Double-Blind, Parallel Group, Multi-center Study to Investigate the Time to Onset of Action of 20 mg Study Drug Compared to Placebo in Males with Erectile Dysfunction A Double-Blind, Placebo-Controlled, Randomized, US/Latin America Study to Evaluate the Effect of Study Drug Prolonged Release on Nocturia in Patients with Symptoms of Overactive Bladder (OAB) A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Study Drug 0.5mg Administered Once Daily for Four Years to Reduce the Risk Of Biopsy-Detectable Prostate Cancer 2003-present A Double-Blind, Placebo-Controlled Study of Frequency and Urgency Using Study Drug 20mg Tablets, Twice Daily, For 12 Weeks Followed by a 6-Month Open-Label Treatment Phase in Patients With Overactive Bladder A Multicenter, Open-Label, Flexible Dose Study to Investigate the Use Pattern of Viagra (sildenafil citrate) And The Ability of Investigators To Further Optimize Subject Satisfaction With Viagra Through Customized Instruction Open-Label Study of the Efficacy and Safety of 5mg and 10mg Study Drug in Patients with Overactive Bladder Symptoms An Open-Label Study to Evaluate the Efficacy and Safety of Study Drug Administered On Demand to Men of Various Populations with Erectile Dysfunction A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Study Drug for the Prevention Of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy 2003-present REALISE: Real Life Safety and Efficacy with Levitra JEFFREY R. THILL,M.D. A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Study Drug Sustained Release in Subjects with Overactive Bladder Syndrome 2003-present Study of Study Drug in Women of Different Demographic 5

6 Characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety 2003-present A Study to Compare the Safety and Efficacy of Once Daily Study Drug Versus Twice Daily Study Drug in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis A Double-Blind, Randomized, Placebo-Controlled Trial of Elmiron For The Treatment of Chronic, Non- Bacterial Prostatitis A Randomized, Double-Blind, Crossover Study to Evaluate the Duration of Erection following Study Drug 10mg Administration for 4 Weeks in a Fixed-Dose Regimen Compared to Placebo In Males with ED An Open-Label, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg Study Drug in Patients Who Wish to Switch from Detrol LA for the Treatment of OveractiveBladder Symptoms Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As Needed Dosing with Study Drug in the Treatment of Premature Ejaculation 2005-present A Multicenter, 2 Week, Double-Blind Study of XXXX 60mg QD Modified Release Capsules and Placebo Given Once Daily In The Morning of In The Evening In Patients with Overactive Bladder 2005-present JEFFREY R. THILL,M.D. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of XXXX for the Prevention of Prostate Cancer in Men with High Grade Prostate Intraepithelial Neoplasia 2005-present 6

7 Updated 2/2005 7

David Henry Jablonski, M.D North Mills Avenue Orlando, FL 32803

David Henry Jablonski, M.D North Mills Avenue Orlando, FL 32803 David Henry Jablonski, M.D. 1812 North Mills Avenue Orlando, FL 32803 EDUCATION: University of Florida College of Medicine, Gainesville, Florida Division of Urology Residency Training Program July 1994-June